RxDoctor Payments Data

Thomas Patterson, MD

Urology · Galesburg, ILNPI 1568460970

Payments from drug & device makers

$2,848in general payments, 2019–2025

Across 78 payments — averaging $36.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Astellas Pharma US Inc$457
  • Olympus America Inc.$106
  • Merck$81
  • Ferring Pharmaceuticals Inc.$60
  • E.r. Squibb & Sons, L.L.C.$56
  • plus $449 from 18 others

What the payments were for

  • Consulting fees$1,39549%
  • Food & beverage$1,45351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,848 in reported general payments places this provider in the 55th percentile of 550 urology providers in Illinois.

See all urology providers in Illinois

Medicare billing

Part B allowed, 2024
$42,324
Medicare patients
208
Services billed
572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron84$45,603
Mirabegron ErMirabegron23$9,998
Fesoterodine Fumarate ErFesoterodine Fumarate11$3,548
Alfuzosin Hcl ErAlfuzosin Hcl210$3,532
Estradiol31$2,280
Testosterone14$1,901
Finasteride109$1,330
Cefdinir59$1,177
Tamsulosin Hcl96$849
Solifenacin Succinate17$581
Dutasteride28$561
NitrofurantoinNitrofurantoin Macrocrystal12$236
Levofloxacin23$104
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim21$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$457$45,60384 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 550 urology providers in Illinois.

Other urology in Galesburg

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →